C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.Its lead product candidate is an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting multiple myeloma and non-Hodgkin lymphomas. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
